Cipher Pharmaceuticals

Cipher Pharmaceuticals is a specialty pharmaceutical company that manages a robust and diversified portfolio of commercial and early to late-stage products. The company acquires products that fulfill unmet medical needs, oversees the necessary clinical development and regulatory approval processes, and markets these products directly in Canada and indirectly through partners in the U.S. and South America. Operating with a lean corporate structure, Cipher employs strategic operational partnerships and engages in both out-licensing and in-licensing of products. Additionally, the company makes selective investments in drug development to build a broad portfolio of prescription products. Cipher’s product pipeline includes Phase III studies for two product candidates, and it markets products in therapeutic areas such as dermatology, GI, women’s health, CNS, urology, immunology, ophthalmology, cardiology, hepatology, and respiratory. The company holds exclusive Canadian license rights for MOB-015 (nail fungus) and CF-101 (moderate to severe plaque psoriasis) and has global rights for DTR-001 (tattoo removal). Cipher also develops and acquires best-in-class skin care solutions for unmet medical needs. Among its marketed products are Actikerall® for hyperkeratotic actinic keratosis, Epuris® for severe acne, Vaniqa® for slowing unwanted facial hair growth in women, Durela® for moderate to moderately severe pain, Aggrastat® for Acute Coronary Syndrome, and Brinavess® for atrial fibrillation. Cipher generates royalty revenue from four successful brands through global partnerships and markets Absorica® for severe acne, ConZip® for chronic pain, and Lipofen® for lipid management in the United States through partnerships with Sun Pharmaceuticals, Vertical Pharmaceuticals, and Ani Pharmaceuticals U.S., respectively.